1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON)
    Meeting Abstract

    Cortes, J. E.; Apperley, J. F.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Health care resource utilization (HCRU) with asciminib and bosutinib among patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs): Results from the multicenter, open-label phase 3 ASCEMBL trial
    Meeting Abstract

    Smith, B. D.; Cortes, J. E.; Rea, D.; Mauro, M. J.; Patwardhan, P.; Maegawa, R.; Zacker, C.; Corbin, R.; Keeping, S.; Sasaki, K.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • AIM4CML trial in progress: A phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutations
    Meeting Abstract

    Levy, M. Y.; Mauro, M. J.; Issa, G. C.; Andorsky, D.; Tomassetti, S.; Maegawa, R.; Shrestha, A.; Deininger, M.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Coombs, C. C.; Pagel, J. M.; Shah, N. N.; Lamanna, N.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; Roeker, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • The Impact of PAP therapy on hematocrit in OSA and polycythemia: A pilot study
    Meeting Abstract

    Jafri, M. H.; Rosa-Acosta, G.; Flores Martinez, J. M.; Schofield, E. A.; Wilkins, C. R.; Mulhall, J. M.; Tan, M.
    American Journal of Respiratory and Critical Care Medicine (2021)

    Fulltext@MSK | Save
  • Management of chemotherapy-ineligible acute myeloid leukemia: Beyond hypomethylating agent monotherapy
    Editorial

    Stein, E. M.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy
    Journal Article

    Zuanelli Brambilla, C.; Lobaugh, S. M.; Ruiz, J. D.; Dahi, P. B.; Goldberg, A. D.; Young, J. W.; Gyurkocza, B.; Shaffer, B. C.; Ponce, D. M.; Tamari, R.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing
    Journal Article

    Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Du, F.; Qu, J.; Chaudhari, J.; Thummar, K.; Zhu, M.; Shen, L. B.; Hall, M.; more...
    Molecular Therapy - Methods & Clinical Development (2021)

    Fulltext@MSK | Save
  • Quaternary and beyond cytoreduction: An updated and expanded analysis
    Journal Article

    Manning-Geist, B. L.; Chi, D. S.; Roche, K. L.; Zivanovic, O.; Sonoda, Y.; Gardner, G. J.; O'Cearbhaill, R. E.; Abu-Rustum, N. R.; Leitao, M. M. Jr
    Gynecologic Oncology Reports (2021)

    Fulltext@MSK | Save
  • Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL
    Journal Article

    Paietta, E.; Roberts, K. G.; Wang, V.; Gu, Z.; Buck, G. A. N.; Pei, D.; Cheng, C.; Levine, R. L.; Abdel-Wahab, O.; Cheng, Z.; more...
    Blood (2021)

    Fulltext@MSK | Save